

Eptinezumab for preventing migraine

Information for the public

Published: 1 March 2023

www.nice.org.uk

Eptinezumab (VYEPTI) is available on the NHS as a possible treatment for preventing migraine in adults if they have:

- migraines on 4 or more days a month and
- tried at least 3 preventive medicines already, which have not worked, or are not tolerated or are unsuitable because of safety concerns.

You will need to stop taking eptinezumab after 12 weeks of treatment if you have:

- episodic migraine (fewer than 15 headache days a month) and the frequency has not reduced by at least 50% (such as from 10 days to 5 days a month)
- chronic migraine (15 headache days a month or more, with at least 8 of those having features of migraine) and the frequency has not reduced by at least 30% (such as from 20 days to 14 days a month).

If you are not eligible for eptinezumab but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on migraine](#) may be a good place to find out more.

[The Migraine Trust](#) (0808 802 0066) can give you advice and support.

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5038-6